In this issue of Blood, Gutsaeva et al describe an aptamer with high affinity for murine P-selectin and its efficacy in preventing vaso-occlusion in a mouse sickle cell disease (SCD) model.1 

Each year, more than 200 000 children are born with SCD,2  yet there is a paucity of treatment options available for sufferers.3  The disease is caused by homozygous expression of a mutation in the beta globin gene which changes a single amino acid (Glu6Val) in the translated protein resulting in assembly of Hemoglobin S (HbS). HbS polymerizes upon deoxygenation giving rise to sickle red cells which are more adhesive than normal red blood cells. The increased adhesive property of sickle red cells causes recurrent vaso-occlusion events in patients and these are associated with increased morbidity and mortality after irreversible organ damage and/or stroke.

A major focus of research in this field has been the use of drugs to stimulate increased expression of Hemoglobin F (HbF) because HbF interferes with HbS polymerization, and patients with high levels of HbF have a milder disease. Most notable among these drugs is hydroxyurea. However, there are concerns about potential side effects of this chemotherapeutic agent and approximately 25% of patients are poor or nonresponders to treatment.4 

An alternative strategy is to target vaso-occlusive episodes. Vaso-occlusion caused by sickle red cells is a complex process involving leukocytes, platelets, and endothelial cells and multiple protein:protein and protein:glycolipid interactions.3  However, inhibitors of some of these interactions cause a major reduction in vaso-occlusion when it is experimentally induced in animal models, suggesting that it may be feasible to develop a single drug capable of preventing and/or reversing vaso-occlusion. One key interaction involves the endothelial integrin αVβ3. Monoclonal antibodies to αVβ3, cyclic pentapeptides containing the integrin recognition motif RGD, and synthetic peptides corresponding to the binding site for αVβ3 on ICAM-4 are very effective inhibitors of vaso-occlusion.5-7  Another key interaction involves endothelial selectins. Sickle red cells adhere to P-selectin on thrombin-treated vascular endothelium and this adhesion is inhibited by heparin.8  A synthetic pan-selectin inhibitor, GMI-1070, with a predominant specificity for E-selectin in vitro, inhibited sickle red cell–leukocyte interactions and improved blood flow and survival of SCD mice.9  Chang et al show that the pan-selectin inhibitor GMI-1070 reduces the number of sickle red cells interacting with adherent leukocytes and consider that E-selectin–induced neutrophil activation is critical for neutrophil-sickle red cell interaction.9 

Gutsaeva et al provide evidence that aptamer ARC5690 directly inhibits endothelial adhesion of both sickle red cells and leukocytes and suggest sickle red cells have an as-yet-unidentified ligand for P-selectin.1  Selectins bind diverse acidic oligosaccharide structures. The sulfated glycolipid isolated from red cells by Hillery et al10  might therefore be a candidate for such a ligand.

Aptamers are single-stranded oligonucleotides isolated by selection for binding to target proteins. Therapeutic efficacy of aptamers has been demonstrated in humans for diseases other than SCD.11  In the Gutsaeva et al study, the 33-mer oligonucleotide (ARC5690) was coupled to a 40-kDa branched polyethylene glycol group to inhibit renal filtration and pro-long the plasma half-life.1  It will be important to assess the effect of repeated exposure to a PEGylated aptamer as other PEGylated products have proved to be immunogenic. Nevertheless, these results represent an exciting development offering the possibility of a much-needed, novel, targeted therapy for patients with SCD.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

1
Gutsaeva
 
DR
Parkerson
 
JB
Yerigenahally
 
SD
, et al. 
Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.
Blood
2011
, vol. 
117
 
2
(pg. 
727
-
735
)
2
Weatherall
 
DJ
The inherited diseases of hemoglobin are an emerging global health burden.
Blood
2010
, vol. 
115
 
22
(pg. 
4331
-
4336
)
3
Frenette
 
PR
Atweh
 
GF
Sickle cell disease: old discoveries, new concepts and future promise.
J Clin Invest
2007
, vol. 
117
 
4
(pg. 
850
-
858
)
4
Steinberg
 
MH
Zhi-Hong
 
L
Barton
 
FB
Terrin
 
ML
Charache
 
S
Dover
 
GJ
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Blood
1997
, vol. 
89
 
3
(pg. 
1078
-
1088
)
5
Kaul
 
DK
Tsai
 
HM
Liu
 
XD
Nakada
 
MT
Nagel
 
RL
Coller
 
BS
Monoclonal antibodies to alphaVbeta3(7E3 and LM609) inhibit sickle cell red blood cell endothelium interactions induced by platelet activating factor.
Blood
2000
, vol. 
95
 
2
(pg. 
368
-
374
)
6
Finnegan
 
EM
Barabino
 
GA
Liu
 
X
Chang
 
H-Y
Jonczyk
 
A
Kaul
 
DK
Small molecule cyclic alphaVbeta3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasooclusion.
Am J Physiol Heart Circ Physiol
2007
, vol. 
293
 (pg. 
H1038
-
H1045
)
7
Kaul
 
DK
Liu
 
XD
Zhang
 
X
, et al. 
Peptides based on alphaV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell endothelial interactions and vaso-occlusion in the microcirculation.
Am J Physiol Cell Physiol
2006
, vol. 
291
 
5
(pg. 
C922
-
30
)
8
Matsui
 
NM
Varki
 
A
Embury
 
SH
Heparin inhibits the flow adhesion of sickle red blood cells to P selectin.
Blood
2002
, vol. 
100
 
10
(pg. 
3790
-
3796
)
9
Chang
 
J
Patton
 
JT
Sarkar
 
A
Ernst
 
B
Magnani
 
JL
Frenette
 
PS
GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.
Blood
2010
, vol. 
116
 
10
(pg. 
1779
-
1786
)
10
Hillery
 
CA
Du
 
MC
Montgomery
 
RR
Scott
 
JP
Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin.
Blood
1996
, vol. 
87
 
11
(pg. 
4879
-
4886
)
11
Paulinska
 
JB
Jima-Stohlawetz
 
P
Gilbert
 
JC
Hutabarat
 
R
Knobl
 
P
A randomized pilot trial of the anti-von Willibrand factor aptamer ARC1779 in patients with type 2b von Willibrand disease.
Thromb Haemost
2010
, vol. 
104
 
3
(pg. 
563
-
570
)
Sign in via your Institution